SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                            -------------------------
                                    FORM 8-K

                 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported) March 5, 2004
                         Commission File Number 000-50583
                              BioVeris Corporation
                           (Exact name of registrant)

       Delaware                                       80-0076765
 (State of organization)                  (I.R.S. Employer Identification No)

               16020 Industrial Drive, Gaithersburg Maryland 20877
              (Address of principal executive offices and zip code)

                                 (301) 869-9800
                         (Registrant's telephone Number)









Item 4. Changes in Registrant's Certifying Accountant

On March 5, 2004, the Audit Committee of the Board of Directors of BioVeris
Corporation (the Company) engaged PricewaterhouseCoopers LLP as the Company's
new independent accountants to replace Deloitte & Touche LLP. The Audit
Committee decided to solicit proposals from independent accounting firms, prior
to the commencement of the audit for the Company's fiscal year ending March 31,
2004. After receiving these proposals and considering a variety of factors, the
Audit Committee voted to dismiss Deloitte & Touche LLP and engage
PricewaterhouseCoopers LLP as the Company's new independent accountants.

The report of Deloitte & Touche LLP on the consolidated financial statements of
the Company for the fiscal years ended March 31, 2003 and 2002 contained no
adverse opinion or disclaimer of opinion and was not qualified or modified as to
uncertainty, audit scope or accounting principles.

In connection with its audits, including those for the two most recent fiscal
years and through March 5, 2004, there have been no disagreements with Deloitte
& Touche LLP on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which disagreements if not
resolved to the satisfaction of Deloitte & Touche LLP would have caused them to
make reference thereto in their report on the Company's consolidated financial
statements for such years.

During the two most recent fiscal years and through March 5, 2004, there have
been no reportable events (as defined in Regulation S-K Item 304(a)(1) (v)).

The Company provided Deloitte & Touche LLP with a copy of the disclosures to be
included in Item 4 of this Form 8-K and requested that Deloitte & Touche LLP
furnish the Company with a letter addressed to the Securities and Exchange
Commission stating whether or not it agreed with the statements made in Item 4.
Attached as Exhibit 16 is a copy of a letter from Deloitte & Touche LLP, dated
March 11, 2004.

During the two most recent fiscal years and through March 5, 2004, the Company
has not consulted with PricewaterhouseCoopers LLP regarding either (i) the
application of accounting principles to a specified transaction, either
completed or proposed; or the type of audit opinion that might be rendered on
the Company's financial statements, and neither a written report was provided to
the Company nor oral advice provided that PricewaterhouseCoopers LLP concluded
was an important factor considered by the Company in reaching a decision as to
the accounting, auditing, or financial reporting issue; or (ii) any matter that
was either the subject of a disagreement, as that term is defined in Item
304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of
Regulation S-K, or a reportable event, as that term is described in Item
304(a)(1)(v) of Regulation S-K.











Item 7. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

          Not Applicable.

(b) Pro Forma Financial Information.

          Not Applicable.

(c) Exhibits.



Exhibit No      Exhibit Description

16 Letter from Deloitte & Touche LLP (filed herewith) to the Securities and
Exchange Commission dated March 11, 2004.


                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

BioVeris Corporation (Registrant)

                                 By:   /s/ Samuel J. Wohlstadter
                                  -----------------------------
                                  Samuel J. Wohlstadter
                                  Chief Executive Officer


Date:  March 11, 2004